A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif®) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis

Daniel Mikol, M. Lopez-Bresnahan, S. Taraskiewicz, P. Chang, J. Rangnow, Mary Angelopoulos, Richard Arazi, Fern Arlen, Paul Ash, Lilly Atalla, William Au, Donald W. Ayres, Khurram Bashir, Ann Bass, Jacqueline Bernard, Christopher Bever, Gary Birnbaurn, Richard Blanck, Susan K. Blue, Andrew BlumenfeldRichard Bodziner, Thor E. Borresen, Michael Bowman, David W. Brandes, Staley A. Brod, Paul Brownstone, James D. Burkholder, Robert Cain, Dominic Cardelli, Mark C. Cascione, Bruce Cleeremans, Stuart Cook, Joanna Cooper, Patricia Coyle, Anne H. Cross, Thomas J. Curfman, Neil Dahlquist, Terry P. Detrich, Vithalbhai D. Dhaduk, Richard A. Dickson, Dennis W. Dietrich, Bhupesh Dihenia, Peter B. Dunne, Charles L. Echols, Lawrence Eilender, Stanton B. Elias, Michael A. Epstein, Nordeli Estronza, Geoffrey A. Eubank, Edward Fox, Stuart Fox, Robert C. Frere, John Gambin, James E. Garrison, Annmarie Gaskin, Suzanne K. Gazda, John Gilroy, David Ginsburg, Ugo Goetzl, Eugene Gosy, Phillip M. Green, Wayne Greene, Jeffrey L. Gross, Joseph B. Guarnaccia, Mark Gudesblatt, Mathews W. Gwynn, Ghazala Hayat, Larry Hollenbeck, W. David Honeycutt, Philip S. Hsu, Bruce Hughes, Barrie J. Hurwitz, Walter G. Husar, Daniel H. Jacobs, Alan K. Jacobs, Riaz A. Janjua, Douglas R. Jeffrey, Jay Kaner, Lloyd Kasper, Michael D. Kaufman, Leslie Kelman, Bhupendra O. Khatri, Peter Kinkel, Stephen Kirzinger, Mariko Kita, Robert L. Knobler, Oldrich J. Kolar, H. Stephen Kott, Ivan R. Landen, Thomas Leist, Nancy Lellelid, Jeffrey R. Levin, Kenneth Levin, William Likosky, Heidi Loganbill, Fred D. Lublin, Sylvia Lucas, Leo Maher, Raul N. Mandler

Research output: Contribution to journalArticlepeer-review

55 Scopus citations

Fingerprint

Dive into the research topics of 'A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif®) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis'. Together they form a unique fingerprint.

Medicine & Life Sciences